Preclinical Characterization and Phase 1 Trial Results of INBRX-109, a Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma
Vivek Subbiah
Investigational New Drugs
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study
Clinical Lung Cancer
Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series
Esmo Open
Sodium fluoride (Na18F) PET Response Criteria in Solid Tumors (NAFCIST): a framework for response assessment in bone tumors
Journal of Comparative Effectiveness Research
For what it’s worth: the complex area of medicine value assessment
Annals of Oncology
Searching for clinical trials in oncology: finding a path through the maze
Trends in Cancer
Tumor-agnostic drug development in dMMR/MSI-H solid tumors
European Journal of Cancer
Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours
Nature Reviews. Clinical Oncology
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
Annals of Oncology
Weight Gain in Cancer Patients Treated with Brain Penetrant RET-selective Inhibitors